Document Detail


Tocilizumab.
MedLine Citation:
PMID:  20065633     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.
Authors:
Adith Venkiteshwaran
Related Documents :
946273 - Systemic mastocytosis associated with presence of rheumatoid factor.
3897533 - A multidot immunobinding assay for autoimmune testing: evaluation for the diagnosis and...
946273 - Systemic mastocytosis associated with presence of rheumatoid factor.
Publication Detail:
Type:  Journal Article; Review     Date:  2009-09-10
Journal Detail:
Title:  mAbs     Volume:  1     ISSN:  1942-0870     ISO Abbreviation:  MAbs     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2010-01-12     Completed Date:  2010-04-05     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  101479829     Medline TA:  MAbs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  432-8     Citation Subset:  IM    
Affiliation:
Rensselaer Polytechnic Institute, Troy, NY, USA. sohini.mazumdar@tufts.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal* / administration & dosage,  adverse effects,  immunology,  therapeutic use
Antibodies, Monoclonal, Humanized
Arthritis, Rheumatoid / drug therapy*
Clinical Trials as Topic
Crohn Disease / drug therapy*
Drug Administration Schedule
European Union
Giant Lymph Node Hyperplasia / drug therapy*
Humans
Japan
Mice
Receptors, Interleukin-6 / immunology*
Treatment Outcome
United States
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Receptors, Interleukin-6; 0/tocilizumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Motavizumab.
Next Document:  Denosumab.